Dr Reddys Labs launches Hyalosyn

Mumbai: The Hyderabad-based Dr Reddys Laboratories (DRL) has launched Hyalosyn (sodium hyaluronate), an intra-articular injection that provides relief from knee-joint stiffness and immobility among patients suffering from severe osteoarthritis. Hyalosyn is being launched under a co-marketing arrangement with Gland Pharma, a pharmaceutical company in Hyderabad well known for the production of pre-filled injectables.

A DRL press release issued here said the introduction of Hyalosyn would further strengthen the companys arthritis franchise in which it is already a leading player in the domestic market. Hyalosyn is an emerging therapy for osteoarthritis known as Viscosupplementation. Hyaluronic acid, the active substance in Hyalosyn, a naturally occurring substance found in Synovial fluid, which surrounds the joints. Hyaluronic acid acts as a lubricant that enables bones to move smoothly over each other and also acts as a shock absorber for joints.

Osteoarthritis is a widely prevalent disease. More than 90 per cent of people above the age of 45 are estimated to show signs of this disease, and it is the leading cause of disability in people above the age of 65. Hyalosyn will be marketed as a sterile, pre-filled syringe containing 20 mg/2ml of sodium hyaluronate. Hyalosyn will provide the much-needed relief to patients suffering from severe osteoarthritis and will enable them to resume their daily activities, the release said.